Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP ZUMARRAGA, Juan Pablo FMUSP-HC
BATISTA, Felipe Augusto Ribeiro FMUSP-HC
CAIERO, Marcelo Tadeu FMUSP-HC
MARTINO, Luis Pablo De La Rosa FMUSP-HC
CAMARGO, Olavo Pires De FMUSP-HC 2018
dc.identifier.citation ACTA ORTOPEDICA BRASILEIRA, v.26, n.5, p.320-324, 2018
dc.identifier.issn 1413-7852
dc.description.abstract Objective: Myxofibrosarcoma (MFS) is a common soft tissue sarcoma (STS) that affects the extremities in elderly patients. The objective was to analyze the prognostic factors and outcomes of patients with MFS treated at a single institution. Methods: We retrospectively reviewed the records of 75 patients with MFS. We compared age, sex, tumor size and location, grade and stage of the disease. Median age was 49.7 years (range, 1 to 88 y). Location: upper extremity (25.4%), lower extremity (66.6%) and pelvis (8%). Patients had high-grade tumors in 46.7% of the reports. Margins were negative in 76% of the cases. Bivariate Cox regression analysis was used to determine associations between clinical and treatment factors with local recurrence (LR). Results: Median follow-up time was 30.7 months (range, 1.8 to 383.8 m). We found 26.7% of LR. Distant metastasis (DM) was reported in 27 (36%) patients. Lung was the most common site of DM, reported in 92.6% of patients. Overall survival (OS) with metastasis was 21.2 months (range, 4.8 to 114.8 m). Predictors of OS were grade, LR (hazard ratio [FIR] 5.13, 95% confidence interval, 2.15-12.24, P <0.001), and DM (HR 540.97, 95% confidence interval, 5.04-58112.03, P< 0.001). Conclusions: Tumor grade, LR, positive margins and DM were significant predictors of poor OS prognosis.
dc.language.iso eng
dc.relation.ispartof Acta Ortopedica Brasileira
dc.rights openAccess
dc.subject Sarcoma; Excision margins; Recurrence; Radiotherapy; Neoplasm metastasis
dc.subject.other high-grade myxofibrosarcoma; sarcoma; variant; impact
dc.type article
dc.rights.holder Copyright ATHA COMUNICACAO & EDITORA LIM/41
dc.identifier.doi 10.1590/1413-785220182605208644
dc.identifier.pmid 30464713
dc.type.category original article
dc.type.version publishedVersion ZUMARRAGA, Juan Pablo:FM: BATISTA, Felipe Augusto Ribeiro:HC:IOT BAPTISTA, Andre Mathias:HC:IOT CAIERO, Marcelo Tadeu:HC:IOT MARTINO, Luis Pablo De La Rosa:HC:IOT CAMARGO, Olavo Pires De:FM:MOT WOS:000448984100007 2-s2.0-85056165998 SCIELO:S1413-78522018000500320 SAO PAULO SP BRAZIL
hcfmusp.relation.reference · Bonvalot S, 2017, ANN SURG ONCOL, V24, P194, DOI 10.1245/s10434-016-5462-2
· Emori M, 2015, J SURG ONCOL, V111, P975, DOI 10.1002/jso.23934
· Hoang Kevin, 2015, Iowa Orthop J, V35, P181
· Hong NJL, 2013, ANN SURG ONCOL, V20, P80, DOI 10.1245/s10434-012-2572-3
· Imanishi J, 2016, ANTICANCER RES, V36, P2339
· Kikuta K, 2017, JPN J CLIN ONCOL, V47, P334, DOI 10.1093/jjco/hyw199
· le Grange F, 2014, EJSO-EUR J SURG ONC, V40, P394, DOI 10.1016/j.ejso.2014.01.011
· Neagu TP, 2017, ROM J MORPHOL EMBRYO, V58, P603
· Odei B, 2017, AM J CLIN ONCOL
· Quimby A, 2017, J ORAL MAXILLOFAC SU, V75
· Randall RL, 2007, ORTHOPAEDIC KNOWLEDG, P277
· Sakamoto A, 2014, SKELETAL RADIOL, V43, P1487, DOI 10.1007/s00256-014-1914-6
· Sambri A, 2016, EJSO-EUR J SURG ONC, V42, P1042, DOI 10.1016/j.ejso.2016.05.015
· Sawamura C, 2010, CLIN ORTHOP RELAT R, V468, P3019, DOI 10.1007/s11999-010-1398-1
· Scoccianti G, 2016, J SURG ONCOL, V114, P50, DOI 10.1002/jso.24250
· Silverstein E, 2007, ORTHOPAEDIC KNOWLEDG, P289
· Stacchiotti S, 2012, CANCER-AM CANCER SOC, V118, P5857, DOI 10.1002/cncr.27624
· Tsuchie H, 2017, UPSALA J MED SCI, V122, P190, DOI 10.1080/03009734.2017.1356404
· WEISS SW, 1977, CANCER, V39, P1672, DOI 10.1002/1097-0142(197704)39:4<1672::AID-CNCR2820390442>3.0.CO;2-C
dc.description.index PubMed
dc.identifier.eissn 1809-4406
hcfmusp.citation.scopus 0
hcfmusp.citation.wos 0

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account